SCHEMBL23809593

SCHEMBL23809593

CC(C)Oc1cccc(-c2cc(N)ncn2)c1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 3/20 0.62
ASIC3 Q9UHC3 1/20 0.57
GABRA1 P14867 1/20 0.49
GABRG2 P18507 1/20 0.49
GABRB3 P28472 1/20 0.49
GABRA5 P31644 1/20 0.49
GABRA3 P34903 1/20 0.49
KMO O15229 1/20 0.47
WDR5 P61964 1/20 0.47
RXRA P19793 1/20 0.47
RXRB P28702 1/20 0.47
TARS1 P26639 4/20 0.46
USP30 Q70CQ3 1/20 0.44
PIM1 P11309 2/20 0.43
PIM3 Q86V86 2/20 0.43
PIM2 Q9P1W9 2/20 0.43
PIK3CA P42336 1/20 0.42
DHFR P00374 1/20 0.42
AAK1 Q2M2I8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL558582 0.86 ASIC3 (0.59) MAP4K4ASIC3KMOPIK3CA
SCHEMBL23221374 0.82 MAP4K4 (0.51) MAP4K4GABRA1GABRG2GABRB3GABRA5
SCHEMBL28049525 0.81 ASIC3 (0.67) MAP4K4ASIC3KMOPIK3CA
SCHEMBL30268116 0.79 ABL1 (0.57) MAP4K4ASIC3KMO
SCHEMBL15587826 0.77 MAP4K4 (1.00) MAP4K4
SCHEMBL8252632 0.76 GABRA1 (0.54) MAP4K4GABRA1GABRG2GABRB3GABRA5
SCHEMBL4666632 0.76 MAP4K4 (0.50) MAP4K4GABRA1GABRG2GABRB3GABRA5
SCHEMBL30469319 0.75 RXRA (0.57) MAP4K4GABRA1GABRG2GABRB3GABRA5
SCHEMBL20557906 0.75 RXRA (0.57) MAP4K4GABRA1GABRG2GABRB3GABRA5
SCHEMBL558453 0.74 ASIC3 (1.00) ASIC3KMOPIM1PIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11370784-B2 Cyano-substituted heterocycles with activity as inhibitors of USP30 MISSION THERAPEUTICS LIMITED (GB) 2022-06-28 US disclosed
US-20210284631-A1 CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LIMITED (GB) 2021-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210284631-A1 CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 USP30, USP28, USP1 MAP4K4 3079/4885ASIC3 4660/4885GABRA1 3520/4885
US-11370784-B2 Cyano-substituted heterocycles with activity as inhibitors of USP30 USP30, USP28, USP1 MAP4K4 3079/4885ASIC3 4660/4885GABRA1 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.